(19) World Intellectual Property Organization International Bureau

AIIPO OMPI

(43) International Publication Date 10 April 2003 (10.04.2003)

PCT

(10) International Publication Number WO 03/028711 A2

(51) International Patent Classification7:

A61K 31/00

(21) International Application Number: PCT/BP02/10827

(22) International Filing Date:

26 September 2002 (26.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/325,491

27 September 2001 (27,09,2001) US

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, 1235 Vienna (AT).

(71) Applicant (for all designated States except US): DANA-FARBER CANCER INSTITUTE INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ANDERSON, Kenneth, C. [US/US]: 264 Weston Road, Wellesley, MA 02482 (US).

(74) Agent: GROS, Florent; NOVARTIS AG, Corporate Intellectual Property, Patent & Trademark Department, 4002 Basel (CH).

(81) Designated States (national): AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, ŁK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, T3, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).


Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF C-KIT INHIBITORS FOR THE TREATMENT OF MYELOMA





(57) Abstract: The present invention relates to the use of a c-kit inhibitor, especially a c-kit inhibitor of formula I, wherein the radicals and symbols have the meanings as defined in the specification, for the preparation of a medicament for the treatment of myeloma, in particular multiple myeloma, especially myeloma which is resistant to conventional chemotherapy; to a combination comprising a c-kit inhibitor and a compound effecting apoptosis of myeloma cells, preferably dexamethasone, for simultaneous, separate or sequential use; to methods of treating myeloma; and to a pharmaceutical composition comprising said combination.

(19) 日本国特許庁(JP)

(12)公表特

(51) Int.C1.7		F 1
A61K	45/00	AGIK
A61K	31/573	A 6 1 K
A61P	35/00	A 6 1 P

特願2003-532044 (P2003-532044) (21) 出願番号 (86) (22) 出願日 平成14年9月26日 (2002.9.26) (85) 翻訳文提出日 平成16年3月10日 (2004.3.10) (86) 国際出願番号 PCT/EP2002/010827 (87) 国際公開番号 W02003/028711 (87) 国際公開日 平成15年4月10日 (2003.4、10) (31) 優先権主張番号 60/325,491 (32) 優先日 平成13年9月27日 (2001.9、27) (33) 優先権主張国 米国 (US)